OCA significantly improved fibrosis in patients with liver fibrosis due to NASH and demonstrated consistent efficacy across multiple histologic and biochemical parameters REGENERATE data to be presented during the Opening Ceremony of EASL NEW YORK , April 11, 2019 (GLOBE NEWSWIRE) -- Intercept
Multiple additional abstracts evaluating obeticholic acid (OCA) for the treatment of patients with progressive non-viral liver diseases to be presented at the meeting NEW YORK , April 04, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on
NEW YORK , March 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the
Positive topline results from pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH: the largest and first successful pivotal Phase 3 NASH study Worldwide Ocaliva net sales of $52.9 million in the fourth quarter of 2018 and $177.8 million in the full
NEW YORK , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2018 financial
First and largest successful pivotal Phase 3 study in patients with liver fibrosis due to NASH OCA achieves primary endpoint demonstrating statistically significant improvement in liver fibrosis without worsening of NASH at 18 months (p=0.0002) Intercept intends to file for regulatory approval in
Top-line data from the interim analysis of the Phase 3 REGENERATE trial of obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis anticipated in Q1 2019 Phase 3 REVERSE trial of OCA in NASH patients with compensated cirrhosis projected to complete enrollment
NEW YORK , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the
NEW YORK , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple obeticholic acid (OCA)
Worldwide Ocaliva net sales of $46.6 million in the third quarter of 2018 Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to report data in the first half of 2019 Conference call scheduled for 8:30 a.m.
